Clinical trials with Alice strain, live, attenuated, serum inhibitor-resistant intranasal influenza A vaccine.
Two clinical trials with Alice strain intranasal influenza vaccine were performed. In study no. 1 (utilizing random selection and double-blind control), 50 subjects received a bivalent inactivated influenza vaccine intramuscularly, 99 subjects received Alice strain vaccine intranasally, and 50 subjects received a placebo intranasally. No symptomatology could be attributed to the intranasal route of immunization. Convalescent-phase geometric mean titers of hemagglutination inhibition antibody were higher after intramuscular vaccination; seroconversion occurred in 16 or 17 recipients of the Alice strain, with initial titers of less than 1:8. Clinical and virologic surveillance for 20 weeks after vaccination revealed no influenza A illnesses in participants of the study. In study no. 2, 75% of the subjects with initial nasal antibody titers of less than 1:3 developed measurable nasal antibody after receiving Alice strain vaccine.
D000281:Administration, Intranasal; D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis; D002986:Clinical Trials as Topic; D046508:Culture Techniques; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D009980:Influenza A virus / Q000302:isolation & purification; D007252:Influenza Vaccines / Q000008:administration & dosage; D007251:Influenza, Human / Q000517:prevention & control*; D007273:Injections, Intramuscular; D008875:Middle Aged; D009666:Nose / Q000276:immunology; D009924:Organ Culture Techniques; D010919:Placebos; D014613:Vaccines, Attenuated / Q000008:administration & dosage
D000914:Antibodies, Viral; D007070:Immunoglobulin A; D007252:Influenza Vaccines; D010919:Placebos; D014613:Vaccines, Attenuated